News

Discovered and developed by Lycera based on technology licensed from the University of Michigan, LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing

The AR-12 orphan drug status was based on application packages that included relevant data from pre-clinical models for each condition. In the application regarding cryptococcosis, results of an

Breo is a fixed-dose combination of fluticasone furoate (FF) and vilanterol (VI) and two strengths, 100/25mcg and 200/25mcg of the combination have been approved in the US for

CF-301 is being developed to be used in combination with standard of care antibiotics for the treatment of Staph bloodstream infections, including infective endocarditis, caused by drug-sensitive and

The patent was issued by the United States Patent and Trademark Office (USPTO) and will be listed in the US Food and Drug Administration’s Approved Drug Products with

Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol

The fifth patient is the third and final patient to be dosed in Cohort 2. The three patients in Cohort 2 received a dose of TT-034 of 1.25

"We are pleased by the FDA’s acceptance of our BLA for Zinbryta, which we believe has the potential to help people living with MS," said Gilmore O’Neill, vice

Xilonix is designed to block chronic inflammation associated with malignant tumor growth. The US Phase III trial was initially launched in March 2013 and patients were enrolled at